Candel Therapeutics an off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.
Needham, MA
Joined January 2019
- Tweets663
- Following151
- Followers804
- Likes170
Our CEO @PaulPeterTak connected with Brad Loncar at @BiotechTV during the @HCWCO Annual Global Investment Conference about the path to BLA filing for aglatimagene in localized prostate cancer and our lung cancer program.
biotechtv.com/post/candel-th…
#BLA #ProstateCancer
Our Chief Scientific Officer @BaroneExpMed spoke with Zach Gobst on the Impactful Breakthroughs podcast about her journey to cancer immunotherapy, her "backpack theory" of continuous growth, and why patients must remain central to drug development.
share.transistor.fm/s/3723ad…
October is National Healthy Lung Month.
Our aglatimagene program targets unmet need in #NSCLC patients with progression despite checkpoint inhibitors. We recently initiated our global phase 3 AURORA trial to advance treatment options.
candeltx.com/
#HealthyLungMonth
#ICYMI We’ve appointed Martine Zimmermann, to our board of directors. She brings 30+ years of regulatory affairs and quality experience across multiple stages of drug development.
citybiz.co/article/901157/ca…
#Leadership
We’re presenting at @sitcancer’s Annual Meeting in November.
Two poster presentations on new data from our aglatimagene besadenovec program in non-small cell lung cancer and clinical findings from linoserpaturev in #glioblastoma.
ir.candeltx.com/news-release…
#SITC26 @baroneExpMed
Our CEO @PaulPeterTak will participate in a fireside chat at the 10th Global Prostate Cancer Summit taking place virtually October 6-8.
Learn more: admetech.org/annual-global-s…
#GPS2026 #ProstateCancer
New data at @ASTRO_org!
Digital pathology analysis demonstrates how aglatimagene activates immune response in localized #ProstateCancer.
The quantitative findings support the clinical benefit observed in our phase 3 trial.
ir.candeltx.com/news-release…
#ASTRO2026
For #ProstateCancerAwarenessMonth, our CEO @PaulPeterTak examines why diagnosis has transformed over two decades, but preventing recurrence in localized prostate cancer treated with curative intent remains an unmet challenge.
Read his @UrologyTimes op-ed urologytimes.com/view/after-…
On #WorldCancerResearchDay, we celebrate the research advancing cancer treatment.
Candel develops multimodal viral immunotherapies for prostate, lung, pancreatic, and brain cancers. Together with researchers and patients, we aim to build a better future.
candeltx.com/
We’re attending @BioCentury Grand Rounds in Amsterdam.
Our CEO @PaulPeterTak will moderate a panel, "Rethinking Autoimmunity," on Sept 25.
conferences.biocentury.com/g…
#Biotech #Innovation
On World Patient Safety Day, we highlight our commitment to safe multimodal viral immunotherapy development.
Patient safety guides every step of our clinical work and research.
#WorldPatientSafetyDay #PatientSafety
We’re presenting new aglatimagene data at @ASTRO_org 2026. Our Chief Scientific Officer, @baroneExpMed, is presenting quantitative digital pathology insights from our phase 3 trial in localized #ProstateCancer.
ir.candeltx.com/news-release…
#ASTRO2026 #Immunotherapy
We’re participating in the H.C. Wainwright Annual Global Investment Conference in New York. Our CEO @PaulPeterTak and CCO Mark Sims will present our corporate and commercial strategy across multiple solid tumor indications.
globenewswire.com/news-relea…
#HCWCO #HCWConference
We’re headed to NY for Citi’s Biopharma Back to School Conference and Cantor’s Global Healthcare Conference.
Our CEO @PaulPeterTak will present a corporate overview and recent highlights.
globenewswire.com/news-relea…
#CitiBioPharma #CantorHealthcare #ProstateCancer
During #ProstateCancerAwarenessMonth, we recognize patients fighting this disease.
Candel is advancing aglatimagene for intermediate- to high-risk localized prostate cancer, with phase 3 data showing meaningful improvements in disease-free survival.
candeltx.com/
Tune-in this @urotoday Journal Club discussion highlighting Candel’s phase 3 trial of aglatimagene. After decades of incremental change in localized #ProstateCancer, this data shows improved disease-free survival with a favorable safety profile.
urotoday.com/video-lectures/…
Our CEO @paulpetertak spoke with Steve Ruddy on Biotech Leadership Conversations about building for resilience, managing risk, and moving fast when the data comes in.
linkedin.com/pulse/biotech-l…
Can we turn a tumor into its own vaccine?
Our MOA video explores aglatimagene besadenovec’s biology in localized #ProstateCancer.
Combining intraprostate administration, valacyclovir, and radiotherapy designed to induce immunogenic cell death and stimulate anti-tumor immunity.
In this @urotoday interview, Dr. Glen Gejerman discusses Candel’s phase 3 trial of aglatimagene, showing improved disease-free survival in localized #ProstateCancer with a favorable safety profile.
urotoday.com/video-lectures/…
$CADL
Today we announced Q2 2026 financial results and corporate updates.
Highlights included a The Lancet Oncology publication, BLA prep for aglatimagene in localized prostate cancer, and initiation of the phase 3 AURORA trial in #NSCLC.
ir.candeltx.com/news-release…
$CADL
